ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCN
Marcus Borenäs, Dan Emil Lind, Adam Lehnberg, Edit Zenténius, Matilda Esselius, Eva Jennische, Joel Johansson, Jikui Guan, Agata Aniszewska, Jimmy Van den Eynden, Bengt Hallberg, Ruth Helen Palmer
This study shows that combining ATR and ALK inhibitors improves survival in MYCN-amplified neuroblastoma mouse models lacking ALK mutations.
bioRxiv · Jul 17, 2025 · PreprintCancer Biology